Featured publications
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
November 2, 2023 | The New England Journal of Medicine
Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development
April 5, 2023 | Frontiers in Molecular Biosciences
Quantifying the nativeness of antibody sequences using long short-term memory networks
December 31, 2019 | Protein Engineering, Design, and Selection
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
March 16, 2019 | Kidney International
Structural prediction of antibody-APRIL complexes by computational docking constrained by antigen saturation mutagenesis library data
February 13, 2019 | Journal of Molecular Recognition
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
January 9, 2019 | EBioMedicine
A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins
November 5, 2018 | Nature Chemistry
Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria
September 14, 2018 | Chembiochem: A European Journal of Chemical Biology
Extending human IgG half-life using structure-guided design.
May 3, 2018 | mAbs
Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
February 9, 2018 | PLoS Neglected Tropical Diseases
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.
May 18, 2017 | Antiviral Research
A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.
October 14, 2016 | https://pubmed.ncbi.nlm.nih.gov/27751627/
The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
March 25, 2016 | Antimicrobial Agents and Chemotherapy